Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Role of Mineralocorticoid Receptor on Modulating Aldosterone Production
NCT02871648Phase 1Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Jan 2016
- Primary completion
- Oct 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypertension (HTN) and cardiovascular diseases (CVD) comparing Placebo, Fludrocortisone and Eplerenone (3 arms). Primary endpoint: Serum aldosterone after angiotensin II infusion at 5 days. Started Jan 2016; status: completed.
02
Drugs
eplerenonefludrocortisone
03
Conditions
hypertension (HTN)cardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT02871648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02871648.